Audentes Therapeutics is a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases. We are leveraging our AAV gene therapy technology platform and proprietary manufacturing expertise to develop programs across three modalities: gene replacement, vectorized exon skipping, and vectorized RNA knockdown. Our product candidates are showing promising therapeutic profiles in clinical and preclinical studies across a range of neuromuscular diseases. Audentes is a focused, experienced and passionate team driven by the goal of improving the lives of patients. If you are interested in learning more about our company, please do not hesitate to contact us.
View Top Employees from Audentes Therapeutics| Website | http://www.audentestx.com |
| Ticker | BOLD |
| Revenue | $6 million |
| Funding | $212.5 million |
| Employees | 447 (447 on RocketReach) |
| Founded | 2013 |
| Address | 600 California St, Fl 17, San Francisco, California 94108, US |
| Phone | (415) 818-1005 |
| Technologies |
JavaScript,
HTML,
PHP
+53 more
(view full list)
|
| Category | Biotechnology, Education, Pharmaceuticals, Science and Engineering, Healthcare, Organizations, Genetics, Power Conversion & Protection Equipment, Health Care, Electronics, Health Diagnostics, Manufacturing, Aerospace & Defense, Business Services |
| Web Rank | 2 Million |
| Keywords | audentes therapeutics, audentes, audentes ttherapeutics, audentes tx, mtm1 gene therapy |
| Competitors | AGTC, Abeona Therapeutics, Homology Medicines, Inc., REGENXBIO Inc., Voyager Therapeutics, Inc. |
| SIC | 37, 372 |
| NAICS | 325, 5417, 54, 541, 32, 3254, 32541 |
Looking for a particular Audentes Therapeutics employee's phone or email?
Audentes Therapeutics Questions
The Audentes Therapeutics annual revenue was $6 million in 2023.
Mathew Pletcher is the Senior Vice President, Division Head, Gene Therapy Research and Technical Operations of Audentes Therapeutics.
447 people are employed at Audentes Therapeutics.
Audentes Therapeutics is based in San Francisco, California.
The NAICS codes for Audentes Therapeutics are [325, 5417, 54, 541, 32, 3254, 32541].
The SIC codes for Audentes Therapeutics are [37, 372].
Top Audentes Therapeutics Employees
-
55+
-
13
-
View
Megan Sullivan
Vice President, Global Customer Experience and Commercial Innovation at Audentes Therapeutics
Boston, Massachusetts, United States33 -
ViewMarnie Harker
Global Downstream Lead, Procurement Excellence at Audentes Therapeutics
California, United States5+5+ -
View
Shannise Brown-Fermin
Head Global Market Access Gene Therapy at Audentes Therapeutics
San Francisco, CA, US12 -
33
Related Companies
